Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time J.M. Carrascosa, N. Rivera, I. Garcia-Doval, G. Carretero, F. Vanaclocha, E. Daudén, F.J. Gómez-García, P. De-la-Cueva-Dobao, E. Herrera-Ceballos, I. Belinchón, M. Alsina, J.L. Sánchez-Carazo, M. Ferrán, J.L. Lopez-Estebaranz, B. Pérez-Zafrilla, M. Llamas, R. Rivera, C. Ferrándiz

Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria: Subanalysis of AEDV EQUIDAD and AME Projects M. Sánchez-Díaz, Á. Flórez, G. Carretero-Hernández, M. Grau-Pérez, I. García-Doval, J.M. Carrascosa-Carrillo

Facial Discoid Dermatosis. A 13-Case Series B. Butrón-Bris, C. Buján, S. Berenguer-Ruiz, L. Martos-Cabrera, P. Rodríguez-Jiménez, J. Fraga, C. Eguren, R. Serrano-Pardo, P. Iranzo, José M. Mascaró, M. Llamas-Velasco, A. Reolid